THTX
USDTheratechnologies Inc. Common Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.790
Kõrge
$2.900
Madal
$2.725
Maht
0.01M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
129.6M
Tööstusharu
Biotehnoloogia
Riik
Canada
Kauplemisstatistika
Keskmine maht
3.06M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Theratechnologies Provides Update on Sale Process
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced that following careful
Soleus Capital Issues Letter to The Board of Theratechnologies
Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ:THTX) (the "Company"), today sent a letter to the Board of
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
Future Pak, LLC ("Future Pak") today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. ("Theratechnologies") (NASDAQ:THTX).
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.